A&L Canada Laboratories Becomes Analytical Testing Facility in Shoppers Drug Mart and TruTrace Pilot Traceability Program

Published: December 2, 2019

A&L Canada Laboratories Becomes Analytical Testing Facility in Shoppers Drug Mart and TruTrace Pilot Traceability Program

A&L Canada Laboratories Inc. (“A&L”), a leader in analytical services and technologies, and TruTrace Technologies Inc., creator of the first fully-integrated blockchain platform that registers and tracks intellectual property for the cannabis industry, today announced that A&L will be one of the inaugural testing facilities in the Shoppers Drug Mart and TruTrace Technologies medical cannabis verification pilot program (the “Pilot Program”).

As announced by Shoppers at the second annual World Cannabis Congress, the Pilot Program is built on TruTrace’s proprietary StrainSecure™ platform, which focuses on testing and verification to confirm the origin, authenticity and quality assurance of cannabis products.

A&L was one of the earliest testing facilities to receive a Health Canada testing license under the Access to Cannabis for Medical Purposes Regulations (ACMPR) and provides a wide range of analytical services to the cannabis industry. A&L was recently presented the award for the Best Testing Facility at the 2019 O’Cannabiz Awards Gala – a national annual event honouring cannabis professionals and companies, recognizing excellence and innovation in the industry.

“We provide the full range of services required by TruTrace and Shoppers, and we are proud to support the transparency and accountability goals of this Pilot Program. Our capabilities in testing through all stages of the cannabis production cycle will fully support the quality assurance mandate of Shoppers,” said Nevin McDougall, President and Chief Commercial Officer of A&L.

“We are very pleased to have secured the support of A&L to provide an essential element of the Pilot Program,” said TruTrace Technologies CEO Robert Galarza. “A fundamental objective of the program is to provide complete assurance to medical patients about the origins and quality of their cannabis. A&L’s testing services are a key aspect of meeting that objective.”

A&L will support the project by working with other pilot partners such as WeedMD Inc. and Zenabis Global to provide final test data on medical cannabis products, validating the functionality of the TruTrace platform and meeting the quality assurance requirements of Shoppers and the Canadian consumer.

The full diagnostic capabilities of A&L Canada Laboratories for the cannabis industry can be found on the company web-site at https://www.alcanada.com/cannabistesting.

Recent News

View All News Items

Latest Article

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

The legalization of cannabis edibles, extracts and topicals will expand the cannabis market and create new opportunities for producers, innovators and investors. According to a recent report from Deloitte, the Canadian market for these new cannabis products is expected to be worth $2.7 billion annually, with edibles accounting for more than half ($1.6 billion).

 

Read Article